Delay of Systemic Therapy Confers a Survival Benefit in Patients with Stage IV Non-Small-Cell Lung Cancer
UICC IV NSCLC patients with a delayed systemic therapy had a better overall survival than those with an early therapy. This observation supports a (qualified) waiting time for systemic therapies. Therapy timing may also be a relevant confounder in clinical studies.
Authors
- Jörg Bäsecke
- Nils Goeken (ORCID: https://orcid.org/0000-0002-9169-353X)
- Joachim Hübner (ORCID: https://orcid.org/0000-0001-8596-2046)
- Tobias Raphael Overbeck (ORCID: https://orcid.org/0000-0002-2579-0171)
- Frank Griesinger (ORCID: https://orcid.org/0000-0002-6822-5498)
- Rike Geiken-Weinstock
- Michael Metz (ORCID: https://orcid.org/0000-0003-2019-7704)
- Ralf G. Meyer
- Peter Staib
Institutions
- Carl von Ossietzky Universität Oldenburg (DE)
- Klinikum Oldenburg (DE)
- Universitätsmedizin Göttingen (DE)
- Sankt-Antonius-Hospital Eschweiler (DE)
- Institute of Clinical Cancer Research (DE)
- Pius Hospital Oldenburg (DE)
- Hannover Clinical Trial Center (Germany) (DE)
- St.-Johannes-Hospital Dortmund (DE)
- Oncology Specialists (US)
- Intelligent Transport Systems Niedersachsen (DE)
Publication Details
- Journal
- Cancers
- Published
- 2025-10-31
- DOI
- https://doi.org/10.3390/cancers17213531
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00